0.64 USD
▲+0.03+4.89%
盘后 0.77 0.00%
2026-09-16
市值
$27.83M
市盈率
—
EPS
-0.25
股息率
—
52 周区间
0.59 – 3.15
成交量
37.85K
Beta
0.89
目标价
—
52W 低 0.5952W 高 3.15
价格走势
公司简介
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to devel...